PT3503885T - Composição farmacêutica e métodos de utilização - Google Patents

Composição farmacêutica e métodos de utilização

Info

Publication number
PT3503885T
PT3503885T PT178422143T PT17842214T PT3503885T PT 3503885 T PT3503885 T PT 3503885T PT 178422143 T PT178422143 T PT 178422143T PT 17842214 T PT17842214 T PT 17842214T PT 3503885 T PT3503885 T PT 3503885T
Authority
PT
Portugal
Prior art keywords
methods
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PT178422143T
Other languages
English (en)
Original Assignee
Foresee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co Ltd filed Critical Foresee Pharmaceuticals Co Ltd
Publication of PT3503885T publication Critical patent/PT3503885T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT178422143T 2016-08-19 2017-08-18 Composição farmacêutica e métodos de utilização PT3503885T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662377427P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
PT3503885T true PT3503885T (pt) 2022-04-19

Family

ID=61197121

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178422143T PT3503885T (pt) 2016-08-19 2017-08-18 Composição farmacêutica e métodos de utilização

Country Status (16)

Country Link
EP (1) EP3503885B1 (pt)
JP (1) JP6771671B2 (pt)
KR (1) KR102199295B1 (pt)
CN (2) CN115252604A (pt)
AU (1) AU2017313897B2 (pt)
BR (1) BR112019003281A2 (pt)
CA (1) CA3034032C (pt)
DK (1) DK3503885T3 (pt)
ES (1) ES2910833T3 (pt)
IL (1) IL264863B1 (pt)
MX (1) MX2019001957A (pt)
NZ (1) NZ751777A (pt)
PT (1) PT3503885T (pt)
RU (1) RU2719450C1 (pt)
SG (1) SG11201901376PA (pt)
WO (1) WO2018035459A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11673884B2 (en) * 2019-11-14 2023-06-13 Foresee Pharmaceuticals Co., Inc. Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
TW202313011A (zh) * 2021-06-08 2023-04-01 逸達生物科技股份有限公司 Mmp抑制劑於治療急性呼吸窘迫綜合症之用途
US20240277670A1 (en) * 2021-06-08 2024-08-22 Yuhua Li Safe use of mmp-12 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
SI2260871T1 (sl) * 2004-04-01 2013-09-30 Pierre Fabre Medicament Kompleksi sestavin, ki vključujejo piroksikam, ciklodekstrin in arginin
AU2005277432B2 (en) * 2004-08-19 2011-11-24 Foresee Pharmaceuticals Co., Ltd. 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase
US20120040970A1 (en) * 2009-04-27 2012-02-16 Al-Ghananeem Abeer M Intranasal delivery system for dantrolene
KR102220259B1 (ko) * 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Bace 매개 app 처리과정을 조절하는 히단토인

Also Published As

Publication number Publication date
CN110035750B (zh) 2022-04-22
KR20190082746A (ko) 2019-07-10
CN110035750A (zh) 2019-07-19
NZ751777A (en) 2020-08-28
WO2018035459A1 (en) 2018-02-22
EP3503885A4 (en) 2020-03-25
CA3034032A1 (en) 2018-02-22
WO2018035459A8 (en) 2018-09-07
AU2017313897A1 (en) 2019-04-04
EP3503885A1 (en) 2019-07-03
BR112019003281A2 (pt) 2019-06-04
IL264863B1 (en) 2024-06-01
DK3503885T3 (da) 2022-06-20
RU2719450C1 (ru) 2020-04-17
EP3503885B1 (en) 2022-03-23
CA3034032C (en) 2021-05-25
CN115252604A (zh) 2022-11-01
IL264863A (pt) 2019-04-30
ES2910833T3 (es) 2022-05-13
KR102199295B1 (ko) 2021-01-07
JP2019524891A (ja) 2019-09-05
SG11201901376PA (en) 2019-03-28
JP6771671B2 (ja) 2020-10-21
AU2017313897B2 (en) 2020-06-18
MX2019001957A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
HK1251153A1 (zh) 一種藥物組合物及其應用
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
GB201817116D0 (en) Pharmaceutical preparation of palbociclic and preparation method thereof
IL252967B (en) Pharmaceutical preparations containing plasminogen and their uses
HK1248531A1 (zh) 免疫調節組合物及其使用方法
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
HK1245086A1 (zh) 處方藥物組成及其製備和使用
HK1251979A1 (zh) 肽組合物和使用方法
IL248090A0 (en) Solid pharmaceutical preparations containing biopterin derivatives and their uses
ZA201703398B (en) Pharmaceutical composition and methods
IL266132B (en) Pharmaceutical formulations and methods for their preparation
HK1245085A1 (zh) 處方藥物組成及其製備和使用
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
HK1245113A1 (zh) 藥物組合物及其用途
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
PT3503885T (pt) Composição farmacêutica e métodos de utilização
EP3253396A4 (en) Probiotic compositions and methods of use
GB201511799D0 (en) Composition and methods of treatment
GB201605127D0 (en) Composition and methods of treatment
IL261794A (en) Preparations and methods for using them
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof